NeoFilera (Taiwan-made PDLLA) — Delayed Nodules, Off-Label Placement & Removal
NeoFilera · NeoFilera S-100 · NeoFilera S-200
A poly-D,L-lactic acid collagen stimulator made in Taiwan, not in Korea as is often assumed. The licence is a domestic-manufacture one (衛部醫器製字第008439號, issued 2025-03-21), held by Chief Biotech and manufactured under contract by Shuo-Nuo Biotechnology in New Taipei; it covers two presentations, S-100 and S-200. The public TFDA record lists no indication at all — the efficacy field reads only "see the approved Chinese labelling" — but the approved insert itself is specific: the product is indicated for correction of the nasolabial folds, at no more than 0.7ml per side per session, and the insert adds in its own warnings that the product is not to be used outside the approved indication. That gap between the public record and the insert is worth stating plainly, because "TFDA does not list it" is often repeated as "there is no approved indication", which is a different claim. Locally it is nicknamed the "pong-pong needle" (澎怦針). How much PDLLA and how much carboxymethylcellulose each vial holds has never been published; the 150mg/50mg figures in circulation are derived from a marketing page ratio, not from any approval document.
Composition
Poly-D,L-lactic acid microspheres in a carboxymethylcellulose carrier, supplied as a freeze-dried powder that is reconstituted before injection; the approved insert gives S-100 4.0cc of diluent and S-200 8.0cc. What the approval documents state is the total weight per vial, 100mg for S-100 and 200mg for S-200, and not how that weight divides between PDLLA and CMC, which has never been published. The 150mg-plus-50mg figure in circulation is the 75:25 ratio from a marketing page, multiplied out. The polymer family is the same as AestheFill (Korean-made PDLLA, 154mg with 46mg CMC per vial), and independent bench work (Polymers, 2025) puts the two at almost the same particle size, 25.0 plus or minus 4.9 microns here against 25.0 plus or minus 4.8 for AestheFill, but opposite in surface texture, smooth here and wrinkled and rough there, and 6.9 times apart in reconstitution time, 141 seconds against 966, which the authors attribute to different manufacturing routes (emulsification versus solvent spray). The same three letters on the box do not make it the same object in the tissue.
Common Complications
Delayed subcutaneous nodules, which the approved insert itself places at 1 to 14 months after injection and sometimes as late as two years; nodules around the eyes that may be visible, with inflammation or discolouration; and, if material enters a vessel, the insert warns of consequences as serious as blindness.
Extraction / Removal Method
Ultrasound-guided micro-extraction of the nodule together with the surrounding fibrotic capsule. Surgical removal is not only our position here: the approved insert lists, as its own management option for nodules, voluntary surgical removal or steroid treatment if required.
Top 5 Patient Complaints
1The Nodule Arrives After Everyone Stopped Watching
The insert puts the window at 1 to 14 months, sometimes two years. Patients are usually discharged from follow-up long before that, so the lump surfaces when the injection no longer feels like the obvious cause and the original clinic is no longer in the picture.
2Injected Where The Insert Says Not To
The insert strongly advises against the orbital area and thin skin, and says not to inject the lips. Nodules around the eyes are listed as a known reaction, and they are the ones patients see in the mirror every day.
3The Dilution Table Read As Permission
One remarks column describing larger dilutions for fine lines and the face generally sits in the same document as an indication limited to the nasolabial folds and a warning against off-label use. The looser line is the one that gets quoted.
4Steroid First, Hollow Later
Steroid injection is one of the two options the insert names, and it does flatten an inflamed nodule. What follows in some patients is fat atrophy around the treated spot, which leaves a depression sitting next to material that is still there.
5Domestic Origin Taken As A Safety Argument
Where a product is made tells you about its supply chain, not about how your tissue answers a PDLLA particle. The reaction pattern in this material family does not change at the border, and the approval file for this one is thinner than most on the shelf: no published per-vial composition, no indication in the public record.
Why Traditional Methods Fail
There is no enzyme for PDLLA, and none for the collagen the body lays down around it. Waiting is the usual advice, but the insert itself describes nodules arriving up to two years out, so waiting can mean watching a nodule organise rather than resolve. Steroid is the other option on the label and buys quiet at the cost of possible fat atrophy at the site. Neither route removes the particles that are provoking the reaction.
The Liusmed Repair Strategy
Ultrasound first, to map how the material actually sits: a single organised nodule and material thinned across several areas are different problems and need different plans. Extraction then takes the nodule with its capsule through a small access point, staged across sessions when the spread is wide, so that the tissue is not opened more than the removal requires.
Dr. Liu's Clinical Perspective
The most useful sentence about this product is one the manufacturer wrote. When an insert lists surgical removal of the nodule as a management option, the question of whether extraction is a legitimate route has already been answered in the approval file, and a patient asking for it is not asking for something unusual. The second useful sentence is the timing: 1 to 14 months, sometimes two years. I meet people who were told their lump could not be the filler because too much time had passed. On the document that governs the product, too much time had not passed.
Recovery Timeline
Swelling settles over 7 to 14 days after each session. Contour keeps refining for 4 to 6 weeks as the dissected plane quiets down. Widely spread material is staged, with 6 to 8 weeks between sessions.
FAQ
Is NeoFilera a Korean product?
No. It holds a Taiwanese domestic-manufacture licence (衛部醫器製字第008439號); the character 製 in the licence number marks it as made in Taiwan rather than imported. Chief Biotech holds the licence and Shuo-Nuo Biotechnology manufactures it under contract in New Taipei. A search of the Korean MFDS database returns nothing for it, which is the expected result for a product that was never registered there. The assumption that it is Korean probably comes from the fact that most PDLLA products reaching Taiwan are.
A lump appeared more than a year after my injection. Can it still be the filler?
It can. The approved insert for this product states that subcutaneous nodules may appear late, between 1 and 14 months after injection, and sometimes as late as two years. This matters because patients are often told that passing the first few months without trouble means they are in the clear. On the approval document, that is not what the window looks like. A late nodule is worth imaging rather than dismissing on timing alone.
Can NeoFilera be dissolved?
No. Hyaluronidase works on hyaluronic acid and does nothing to PDLLA, and no enzyme dissolves the collagen your own tissue builds around the particles. Once a nodule has encapsulated, physical extraction is the practical route, which is also the route the product insert itself names.
I was injected across the whole face, but the approved indication is the nasolabial folds only. What does that mean?
Two separate things get mixed here. The insert has a reconstitution table whose remarks column describes larger dilutions as being for fine wrinkles and the face generally, and that line is often read as approval for full-face use. The indication section of the same insert names only the nasolabial folds, with a ceiling of 0.7ml per side per session, and the warnings section says the product is not to be used outside the approved indication. Wider dilution instructions are not an expanded indication. Use outside the approved indication is a decision your injector made, and it is a fair question to put to them; for us it changes the planning of an extraction, because material spread thin across several areas behaves differently from a single depot.
Related Symptoms
References
- TFDA 醫療器材許可證 衛部醫器製字第008439號（妮芙蕾皮下填補劑 NEOFILERA Dermal Filler）
- 妮芙蕾皮下填補劑 中文核定仿單（晶鑽生醫股份有限公司）
This information is for educational purposes only. Treatment options depend on individual circumstances. Consult a qualified physician.
Read next: when this material goes wrong
Case-by-case decisions, written by Dr. Ta-Ju Liu
AestheFill Lumps After Failed 5-FU? Extraction Solutions
5-FU and steroids didn't fix your AestheFill lumps? Ultrasound-guided extraction targets PDLLA nodules and uneven texture that medications can't resolve.
Collagen Stimulator Booster Lumps: Why They Won't Dissolve
Collagen-stimulator skin boosters can leave dermal nodules hyaluronidase cannot act on. Why microdroplet lumps resist dissolving, and how to remove them.
How Collagen Stimulators Work: Why 'Growing Your Own Collagen' Can Go Wrong
The molecular science behind collagen stimulators — and why the 'natural' collagen they produce can become the hardest complication to reverse.